KALV - KalVista Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
16.66
+1.82 (+12.26%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close14.84
Open15.27
Bid9.60 x 900
Ask18.00 x 1300
Day's Range14.94 - 16.96
52 Week Range5.48 - 16.96
Volume166,765
Avg. Volume28,276
Market Cap209.568M
Beta2.57
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Trade prices are not sourced from all markets
  • Business Wire15 days ago

    KalVista Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018, at 3:40 p.m. ET in New York, NY. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • GlobeNewswire15 days ago

    Kalvebod Plc - Series 2 - Full Redemption

    NYKREDIT BANK A/S Kalvebod Brygge 1-3 DK-1780 Copenhagen V Denmark. Copenhagen Stock Exchange Nikolaj Plads 6– Postbox 1040 Copenhagen 1007. Kalvebod plc 6 th Floor, Pinnacle 2 Eastpoint Business Park ...

  • Business Wire22 days ago

    KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

    – KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema –

  • GlobeNewswire2 months ago

    Kalvebod Plc - Series 2 Notice re Coll Redemption

    NYKREDIT BANK A/S Kalvebod Brygge 1-3 DK-1780 Copenhagen V Denmark. Copenhagen Stock Exchange Nikolaj Plads 6– Postbox 1040 Copenhagen 1007. Kalvebod plc 6 th Floor, Pinnacle 2 Eastpoint Business Park ...

  • GlobeNewswire2 months ago

    Recent Analysis Shows Cigna, Basic Energy Services, KalVista Pharmaceuticals, QuinStreet, Armstrong World Industries, and NMI Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, June 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cigna ...

  • GlobeNewswire2 months ago

    Kalvebod Plc - Series 2 Notice re Possible Redemption

    Terms used in this notice and not otherwise defined herein shall have the meanings ascribed to them in the prospectus dated 1 May 2006 in respect of the Notes (the “Prospectus”). On behalf of the Issuer, in our capacity as Listing Agent, we hereby notify you that, subject to the approval of Finanstilsynet, due to a refinancing of certain outstanding obligations of the issuer of the Collateral, Den Jyske Sparekasse (formerly Sparekassen Farsø) a full repayment of the securities forming the Collateral of the Notes is expected to occur following the refinancing which is scheduled to occur on 25 June 2018. Such repayment would result in the redemption of the Notes pursuant to Paragraph 13(A) of the Terms of the Notes.

  • Business Wire3 months ago

    KalVista Pharmaceuticals to Present at Jefferies Healthcare Conference

    KalVista Pharmaceuticals, Inc. (KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 8, 2018, at 9:30 a.m. ET in New York, NY. A live webcast of the presentation may be accessed on the Investors section of the Company’s website at www.kalvista.com. KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.

  • Business Wire3 months ago

    KalVista Pharmaceuticals Presents Data at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2018

    “We are pleased to have developed a proprietary immunoassay to characterize the effects of our novel orally-available plasma kallikrein inhibitor, KVD900, in development for treatment of hereditary angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of KalVista. “Using this method, we are able to demonstrate that KVD900 protects high molecular weight kininogen from plasma kallikrein mediated cleavage in HAE and control plasma.

  • Business Wire3 months ago

    KalVista Pharmaceuticals Recognizes HAE Day

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced recognition of patient organizations from around the world holding a global awareness day for the condition hereditary angioedema .

  • Business Wire4 months ago

    KalVista Pharmaceuticals Presents Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced data in support of the Company’s development activities in diabetic macular edema from an oral presentation at The Association for Research in Vision and Ophthalmology 2018 Annual Meeting in Honolulu, Hawaii.

  • Business Wire4 months ago

    KalVista Pharmaceuticals to Present Data at The Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that data in support of KalVista’s ongoing development in diabetic macular edema has been accepted for oral presentation at The Association for Research in Vision and Ophthalmology 2018 Annual Meeting on May 1, 2018 ...

  • ACCESSWIRE5 months ago

    Wired News – Sangamo Therapeutics’ Preclinical Study Data from MPS II in Vivo Genome Editing Program Published in Molecular Therapy

    Stock Monitor: KalVista Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 6, 2018 / Active-Investors.com has just released a free research report on Sangamo Therapeutics, Inc. (NASDAQ: SGMO ...

  • Business Wire5 months ago

    KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal third quarter ended January 31, 2018.

  • Business Wire6 months ago

    KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a corporate overview at the ROTH Conference on Monday, March 12, 2018, at 2:30 p.m.

  • Business Wire8 months ago

    KalVista Pharmaceuticals Commences Two Clinical Trials

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the initiation of two clinical trials: a Phase 2 proof-of-concept clinical trial evaluating the safety, tolerability, and efficacy of KVD001 as a treatment for diabetic macular edema , as well as a Phase 1 trial ...

  • Business Wire8 months ago

    KalVista Pharmaceuticals Reports Fiscal Second Quarter Results

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today reported operational and financial results for the fiscal second quarter ended October 31, 2017.

  • Business Wire9 months ago

    KalVista Pharmaceuticals to Present at Stifel Healthcare Conference

    KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, November 15, 2017, at 8:00 a.m.

  • KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check
    Simply Wall St.10 months ago

    KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check

    KalVista Pharmaceuticals Inc (NASDAQ:KALV) is a small-cap stock with a market capitalization of USD $99.96M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • ACCESSWIRE10 months ago

    KalVista, Notable Investment and Collaboration Agreement

    NEW YORK, NY / ACCESSWIRE / October 17, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...